A5035629448- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Kruppel-like factors research
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Blood groups and transfusion
- Protein Degradation and Inhibitors
- Erythrocyte Function and Pathophysiology
- Chemotherapy-induced cardiotoxicity and mitigation
- Blood properties and coagulation
- Hemoglobinopathies and Related Disorders
- Synthesis and Characterization of Heterocyclic Compounds
- Immunodeficiency and Autoimmune Disorders
- Research on Leishmaniasis Studies
- Renal Diseases and Glomerulopathies
- Bone and Joint Diseases
- Foreign Language Teaching Methods
- Eastern European Communism and Reforms
- Complement system in diseases
Pirogov Russian National Research Medical University
2017-2025
Botkin Hospital
2016-2025
Ministry of Health of the Russian Federation
2014-2025
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2017-2025
City Clinical Hospital
2016-2024
Cleveland Clinic
2023
University Hospital Dubrava
2023
GlaxoSmithKline (United States)
2023
Endocrinology Research Center
2011-2012
V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs
2011
Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As age, they become less tolerant to treatment, requiring convenient/tolerable/lenalidomide-free options. Carfilzomib and/or bortezomib-exposed/intolerant, lenalidomide-refractory MM with ≥2 prior were randomized 3:2 ixazomib-dexamethasone (ixa-dex) (n = 73) or pomalidomide-dexamethasone (pom-dex) 49) until progression/toxicity. Median...
The development of National clinical guidelines on diagnosis and treatment Ph-negative myeloproliferative neoplasms comes in response to the need standardize approach treatment. availability can facilitate choice adequate strategy, provides practicing physicians with exhaustive up-to-date information advantages shortcomings different methods as well lets health professionals better assess expected extents required by patients. In 2013 a working group was formed develop formulate neoplasms....
Background. There is little information about ophthalmological manifestations of myelofibrosis (MF), their dependence on hematological, morphological, genetic parameters, and eye damage during therapy, there are no publications changes targeted therapy. Aim. To study the spectrum frequency primary, post‑polycythemic, post‑thrombocythemic MF at diagnosis Materials methods. A prospective single‑center controlled included 128 people: 98 patients with in chronic phase (17 onset, 30 long‑term...
Background. Information on the epidemiological picture of chronic myeloid leukemia (CML) and, especially, Ph – myeloproliferative neoplasm (MPN) in Russia is very scarce, each regional population study important for obtaining information diseases general. Aim. To analyze parameters most common MPN over a long period time (2012–2023). Materials and methods. Clinical epidemiological, population, retrospective-prospective, observational CML classical (polycythemia vera, essential...
Background. Mastocytosis is a group of diseases characterized by tumor proliferation mast cells and their accumulation in organs tissues, including skin, hematopoietic (bone marrow, spleen, lymph nodes), the gastrointestinal tract, which clinically manifested symptoms cell activation organ infiltration form hepatosplenomegaly, portal hypertension, ascites, cytopenia. Of greatest scientific clinical interest systemic mastocytosis (SM), where indolent (indolent SM, smoldering SM with isolated...
Background . The T315I mutation in BCR::ABL1 kinase domain determines the resistance of leukemia cells to tyrosine inhibitors (TKIs) – imatinib and secondgeneration TKIs patients with chronic myeloid (CML). impact new T315I-targeted approaches on treatment outcomes is being actively studied. Aim To evaluate clinical characteristics therapy chronic-phase CML practice. An additional objective overall survival (OS) by considering provided. Materials methods non-interventional retrospective...
Aim. To study the epidemiology of multiple myeloma in city Moscow and compare results obtained with data from similar studies other countries. Materials methods. The is based on information a database case histories 3942 patients suffering symptomatic MM, residents Moscow, which maintained at Hematologic City Center S.P. Botkin Municipal Clinical Hospital. control completeness inclusion was carried out by cross - comparison Cancer Register Program 7 (beginning 2019 12) Highly Expensive...
Background. Targeted therapy is the most promising in treatment of myelofibrosis, but it necessary to search for reasons limiting its effectiveness. There are known factors negatively affecting development data on their negative impact context targeted scarce. Aim. Assessing cytogenetic and genetic abnormalities course results primary secondary myelofibrosis during ruxolitinib therapy. Materials methods. The prospective study included 106 patients with chronic phase (53 (50 %) men 53 women)...
The development of National clinical guidelines on diagnosis and treatment Ph-negative myeloproliferative neoplasms provides the knowledge basis for decision making in diagnosis, therapy, prevention, rehabilitation compliance with evidence-based medicine principles order to ensure appropriate medical care a particular setting. underly choice optimal methods as part patient’s care, criteria assessment quality, standards, procedures, setting standards equipment management diagnostic...
Background. The COVID-19 pandemic, which swept the world in 2020–2021, had a significant impact on epidemiological picture of hematological malignancies. Aim. To study dynamics indicators five chronic hemoblastoses Moscow over 12-year period, and also to assess pandemic these indicators. Materials methods. A population-based was conducted for types oncohematological diseases: multiple myeloma, Hodgkin's lymphoma, follicular lymphocytic leukemia, myeloid leukemia. annual rates morbidity,...
Background . Currently, targeted therapy is the most promising for treatment of myelofibrosis (MF). Today, results many years experience with use ruxolitinib, including outside randomized trials and identification predictors its effectiveness are important. Aim To evaluate long-term ruxolitinib in patients primary secondary MF resistant to standard compare patient groups depending on age, gender, clinical, laboratory morphological parameters. Materials methods The prospective study included...
Background. Primary immune thrombocytopenia (ITP) is an orphan disease characterized by decreased platelet count in the peripheral blood which some cases can cause bleeding of varying severity. Currently, use thrombopoietin receptor agonists (TPO-RAs) recommended as second line therapy for ITP it allows to achieve high response (PR), including complete, 73 % chronic and 87 newly diagnosed disease. The mechanism action differs different TPO-RAs. Given this fact, resistance or intolerance with...
Aim. To study the quality of life in patients with chronic immune thrombocytopenia (ITP) process romiplostim therapy and to assess efficacy safety this drug real-world setting.
 Materials & Methods. The enrolled adult confirmed ITP diagnosis indications for therapy. Clinical parameters, RAND SF-36 FACT-Th6 as well FACIT-Fatigue scores were evaluated prior administration vs. 3, 6, 12 months after treatment onset. Patient satisfaction checklist was also administered at all points...
To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP real-world clinical practice.The article contains results analysis application under real practice conditions 138 (40 men 98 women) whose median age at beginning therapy was 59 (18-86) years. Two medicines-romiplostim (100 patients) eltrombopag (38 were used.During first month therapy, platelet count romiplostim group increased from 17·109 / L to 60·109 (9-600·109 L), elethrombopag 16.109 56.109...
Aim. To develop a Russian version of MPN10 form for patients with myeloproliferative neoplasms (MPN) compliant international recommendations. Materials & Methods. The study included 57 treated in 2019 at the Hematology Center Botkin Hospital (n = 30) and Research Institute Transfusiology 27). Among them there were 36 myelofibrosis, 9 polycythemia vera, 12 essential thrombocythemia patients. Mean age was 54.6 years (standard deviation 15.9 years; range 20-79 years). male/female ratio...
Introduction. Given the possibility of preserving molecular remission in 40–60 % patients with chronic myeloid leukemia (CML) a stable deep response (MR) after discontinuation tyrosine kinase inhibitors (TKI), it is important to determine number candidates for observation treatment-free (TFR) and terms treatment cancellation. Aim — evaluate probability MR rate who meet criteria TFR Russian part international multicenter prospective population study EUTOS PBS (European Treatment Outcome Study...
COVID-19 and other infectious diseases can exacerbate the course of paroxysmal nocturnal hemoglobinuria (PNH). The efficacy safety Gam-COVID-Vac vaccine in patients with PNH has not been adequately studied. A retrospective, observational, cohort, non-comparative study was performed to assess as well (Sputnik V) included data from 52 aged 18 75 years, 38 whom received background therapy eculizumab (Elizaria®) between March 2020 January 2022. diagnosed according results PCR testing. were...